S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:MIRM

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

$25.98
-0.79 (-2.95%)
(As of 03/18/2024 ET)
Today's Range
$25.64
$26.94
50-Day Range
$25.98
$29.93
52-Week Range
$21.83
$35.56
Volume
789,916 shs
Average Volume
610,994 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.11

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.13 Rating Score
Upside/​Downside
100.6% Upside
$52.11 Price Target
Short Interest
Bearish
16.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
0.87mentions of Mirum Pharmaceuticals in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$248,102 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.16) to $0.79 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

189th out of 947 stocks

Pharmaceutical Preparations Industry

84th out of 435 stocks

MIRM stock logo

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Stock Price History

MIRM Stock News Headlines

The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 3.9%
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $27.77
MIRM Mar 2024 40.000 call
8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
See More Headlines
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
249
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.11
High Stock Price Target
$72.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+100.6%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-160,900,000.00
Pretax Margin
-112.82%

Debt

Sales & Book Value

Annual Sales
$186.37 million
Book Value
$3.85 per share

Miscellaneous

Free Float
35,399,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
1.16
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Christopher PeetzMr. Christopher Peetz (Age 45)
    CEO & Director
    Comp: $1.09M
  • Mr. Peter Radovich M.B.A. (Age 46)
    Ph.D., COO & President
    Comp: $732.15k
  • Dr. Pamela Vig Ph.D. (Age 53)
    Chief Scientific Officer & Head of Research
    Comp: $678.2k
  • Ms. Lara Longpre MBA (Age 54)
    MSC, Chief Development Officer
    Comp: $678.2k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 64)
    Chief Financial Officer
  • Andrew McKibben
    Vice President of Investor Relations and Finance
  • Mr. Paul K. Ross
    Chief Compliance Officer
  • Ms. Erin Campany (Age 56)
    Senior Vice President of Human Resources
  • Dr. Ian Clements Ph.D. (Age 55)
    Consultant
    Comp: $649.1k
  • Ms. Vinita P. Kumar
    Senior vice President of Quality

MIRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings
or view top-rated stocks.

What is Mirum Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 1-year target prices for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $35.00 to $72.00. On average, they predict the company's share price to reach $52.11 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price.
View analysts price targets for MIRM
or view top-rated stocks among Wall Street analysts.

How have MIRM shares performed in 2024?

Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of the year. Since then, MIRM shares have decreased by 12.0% and is now trading at $25.98.
View the best growth stocks for 2024 here
.

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MIRM earnings forecast
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) released its quarterly earnings data on Monday, November, 15th. The company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.08. The business had revenue of $5 million for the quarter, compared to analysts' expectations of $5 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative trailing twelve-month return on equity of 74.95%. During the same period in the prior year, the company posted ($0.86) EPS.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

What guidance has Mirum Pharmaceuticals issued on next quarter's earnings?

Mirum Pharmaceuticals issued an update on its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $186.0 million-$188.0 million, compared to the consensus revenue estimate of $185.4 million.

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (13.93%), Eventide Asset Management LLC (5.71%), Vanguard Group Inc. (5.31%), Vanguard Group Inc. (5.31%), Cadian Capital Management LP (4.15%) and Price T Rowe Associates Inc. MD (2.50%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends
.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MIRM) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners